Comparative Pharmacology
Head-to-head clinical analysis: FOAMCOAT versus THERMAZENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOAMCOAT versus THERMAZENE.
FOAMCOAT vs THERMAZENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOAMCOAT is a proprietary fibrin sealant containing human fibrinogen and thrombin. When applied topically, thrombin converts fibrinogen into fibrin monomers that polymerize into a stable clot. This forms a mechanical barrier and promotes hemostasis through the final step of the coagulation cascade.
Silver sulfadiazine acts by releasing silver ions that bind to microbial DNA and cell membranes, inhibiting bacterial replication and causing cell death. It also has anti-inflammatory effects by modulating cytokine release.
FOAMCOAT is a topical hemostatic agent; standard adult dose is 1 to 2 mL applied directly to bleeding site, repeated as needed.
1% cream applied topically once or twice daily; for burns, apply 1/16-inch thick layer over entire burn area.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is approximately 22 hours (range 17–28 h) in patients with normal renal function, enabling twice-daily dosing in most cases.
Primarily renal excretion of intact drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Renal: ~65% unchanged; biliary/fecal: ~35% as metabolites and unchanged drug.
Category C
Category C
Topical Antibiotic
Topical Antibiotic